Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailLe medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme insulinosecretagogue dans le traitement du diabete de type 2.
Scheen, André ULg; Van Gaal, L. F.

in Revue Médicale de Liège (2008), 63(2), 105-9

Sitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1). This hormone is mainly secreted by ileal L cells and this ... [more ▼]

Sitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1). This hormone is mainly secreted by ileal L cells and this secretion is abnormally low in patients with type 2 diabetes. Sitagliptin increases post-meal insulin secretion ("incretin effect) by enhancing the postprandial GLP-1 response ("incretin enhancer"), in a glucose-dependent manner. It improves glycaemic control (HbA1c) in type 2 diabetic patients treated by diet alone, by metformin, by sulfonylurea, by glitazone or by a metformin-sufonylurea combined therapy. The glucose-lowering effect is similar to that of glipizide, but with the advantage of no weight gain and no hypoglycaemic episodes. The tolerance to sitagliptin is excellent. Treatment is simple, with 100 mg once daily, without need of titration or home blood glucose monitoring. In Belgium, sitagliptin is currently reimbursed in patients with type 2 diabetes not adequately controlled with diet and metformin monotherapy. [less ▲]

Detailed reference viewed: 277 (2 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Valdecoxib (Bextra)
Scheen, André ULg; Malaise, Michel ULg

in Revue Médicale de Liège (2004), 59(4), 251-254

Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic ... [more ▼]

Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic treatment of osteoarthritis or rheumatoid arthritis (10 to 20 mg once a day) and for the treatment of primary dysmenorrhea (40 mg once a day). Valdecoxib is as efficacious as conventional non-COX-2 selective NSAIDs, but offers the advantage of a much better gastrointestinal tolerance. Valdecoxib has a prodrug that can be administered intravenously or intramuscularly (parecoxib, Dynastat) and has been developed for the short-term treatment of postsurgical pain. [less ▲]

Detailed reference viewed: 107 (1 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois. Vildagliptine (Galvus) et combinaison fixe vildagliptine-metformine (Eucreas) dans le traitement du diabete de type 2.
Scheen, André ULg; Paquot, Nicolas ULg

in Revue Médicale de Liège (2009), 64(3), 161-7

Vildagliptin (Galvus) is a selective inhibitor of dipeptidylpeptidase-4, an enzyme involved in the metabolism of glucagon-like peptide-1 (GLP-1) secreted by L cells of the intestine. It potentiates the ... [more ▼]

Vildagliptin (Galvus) is a selective inhibitor of dipeptidylpeptidase-4, an enzyme involved in the metabolism of glucagon-like peptide-1 (GLP-1) secreted by L cells of the intestine. It potentiates the insulin secretory response (incretin effect) by enhancing the endogenous post-prandial response of GLP-1 (incretin enhancer) in a glucose-dependent manner. Vildagliptin is indicated in the treatment of type 2 diabetes. It improves blood glucose control (HbA1c) in patients treated by diet alone, metformin, sulfonylurea, glitazone or insulin. In patients not well controlled with metformin alone, the addition of vildagliptin is as effective in reducing HbA1c as the coadministration of glimepiride or pioglitazone. Tolerance of vildagliptin is excellent, with no weight gain and no hypoglycaemic episodes. Treatment is simple, with two doses of 50 mg per day, without need of titration or home blood glucose monitoring. In Belgium, vildagliptin is currently reimbursed for the treatment of type 2 diabetes after diet failure and monotherapy with metformin. Therapy can be administered separately or by using a fixed combination vildagliptin-metformin (Eucreas), which should improve drug compliance. [less ▲]

Detailed reference viewed: 245 (2 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois: Linagliptine (Trajenta): un inhibiteur selectif de la DPP-4 a elimination renale negligeable.
SCHEEN, André ULg; Van Gaal, L. F.

in Revue Médicale de Liège (2012), 67(2), 91-7

Linagliptin (Trajenta) is a selective inhibitor of dipeptidyl peptidase-4, an enzyme that degrades two incretin hormones, GLP-1 ("Glucagon-Like Peptide-1") and GIP ("Glucose-dependent Insulinotropic ... [more ▼]

Linagliptin (Trajenta) is a selective inhibitor of dipeptidyl peptidase-4, an enzyme that degrades two incretin hormones, GLP-1 ("Glucagon-Like Peptide-1") and GIP ("Glucose-dependent Insulinotropic Polypeptide"). As other molecules belonging to this pharmacological class, linagliptin improves blood glucose control of type 2 diabetic patients, without increasing hypoglycaemic risk, without promoting weight gain and with a good clinical and biological tolerance profile. Both efficacy and safety have been demonstrated in randomized controlled trials as monotherapy or in combination with other glucose-lowering agents, independent of demographic or clinical patient's characteristics. The pharmacokinetics specificity of linagliptin comprises its biliary excretion, with low hepatic metabolism (no drug-drug interactions) and, in contrast to other gliptins, its negligible renal elimination. Because of these favourable properties, linagliptin may be used without dose adjustment (5 mg once a day) in patients with renal impairment, as well as in elderly people. [less ▲]

Detailed reference viewed: 59 (0 ULg)
Full Text
Peer Reviewed
See detailLe medicament du mois: Olmesartan medoxomil (Belsar ou Olmetec)
Krzesinski, Jean-Marie ULg; Scheen, André ULg

in Revue Médicale de Liège (2004), 59(10), 607-611

Olmesartan medoxomil (Belsar, Olmetec) developed by Sankyo Pharma and proposed by Sankyo Pharma but also Menarini is a new angiotensin II ATI receptor blocker. Its indication is the treatment of ... [more ▼]

Olmesartan medoxomil (Belsar, Olmetec) developed by Sankyo Pharma and proposed by Sankyo Pharma but also Menarini is a new angiotensin II ATI receptor blocker. Its indication is the treatment of hypertension. Olmesartan is indeed an antihypertensive agent with an efficacy dependent on the dose from 10 to 40 mg. It is taken once a day, because of a long duration of action. This prodrug has a dual elimination pathway (biliary and renal). The contraindications are the same as for the other sartans. One of its main advantage, besides its rapidly observed efficacy to lower high blood pressure, is its relatively low cost within this family. It has also cardiovascular and renal protective effects. The recommended usual dosage is 20 mg/day. [less ▲]

Detailed reference viewed: 363 (9 ULg)
Peer Reviewed
See detailLe médicament parmi les thérapies relationnelles : Enquête et réflexions.
David, Claire; WAUTHY, Jacques ULg; Vaulet, Véronique et al

in Revue des Hôpitaux de Jour Psychiatriques et des Thérapies Institutionnelles (2001)

Detailed reference viewed: 18 (5 ULg)
See detailLe médicament, la fourrure et le bâti. Le castor et ses modes d'existence
Strivay, Lucienne ULg

Article for general public (2011)

Detailed reference viewed: 42 (7 ULg)
Peer Reviewed
See detailMédicaments anti-asthmatiques. De la pharmacologie à la clinique
Louis, Renaud ULg; Radermecker, Maurice ULg

in Revue Médicale de Liège (1991), 46(2), 58-81

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailLes médicaments estampillés dans la littérature médicale latine
Marganne, Marie-Hélène ULg

in Defosse, Pol (Ed.) Hommages à Carl Deroux. II. Prose et linguistique, médecine (2002)

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailLes médicaments estampillés dans le Corpus galénique
Marganne, Marie-Hélène ULg

in Debru, Armelle (Ed.) Galen on Pharmacology. Philosophy, History and Medicine. Proceedings of the Vth International Galen Colloquium, Lille, 16-18 March 1995 (1997)

Detailed reference viewed: 48 (5 ULg)
Peer Reviewed
See detailMedicaments et grossesse.
Scheen, André ULg

in Revue Médicale de Liège (1999), 54(5), 409-14

Since the dramatic observations of fetal abnormalities associated to thalidomide use during pregnancy, the risk of malformations when prescribing drugs in pregnant women is a well-known problem, among the ... [more ▼]

Since the dramatic observations of fetal abnormalities associated to thalidomide use during pregnancy, the risk of malformations when prescribing drugs in pregnant women is a well-known problem, among the public as well as among medical doctors. However, the complexity of the problem, the lack of robust scientific data and the emotional context characterizing this period make the prescription of medications to a pregnant woman a difficult task for every people involved in health care, the pharmacist, the general practitioner and even the gynaecologist. [less ▲]

Detailed reference viewed: 28 (2 ULg)
Full Text
Peer Reviewed
See detailMedications in the kidney.
Scheen, André ULg

in Acta Clinica Belgica (2008), 63(2), 76-80

Patients with chronic kidney disease (CKD) constitute a population at high risk for adverse drug reactions and/or drug-drug interactions. Renal dysfunction-induced pathophysiological changes may alter ... [more ▼]

Patients with chronic kidney disease (CKD) constitute a population at high risk for adverse drug reactions and/or drug-drug interactions. Renal dysfunction-induced pathophysiological changes may alter both medication pharmacodynamics and handling. Most pharmacokinetic parameters are adversely affected by impaired kidney function, among which reduced glomerular filtration and altered tubular secretion and reabsorption lead to the most specific alterations. Dosages of drugs cleared by the kidney should usually be adjusted according to creatinine clearance. Recommended methods for maintenance dosing adjustments are dose reductions, lengthening the dosing interval, or both. Appropriate drug selection and dosing in patients with CKD is imperative to avoid drug adverse events and to ensure optimal patient outcomes. [less ▲]

Detailed reference viewed: 59 (5 ULg)
Full Text
See detailMedici et Medica. 2e édition. État au 15 janvier 1997 du fichier MP3 pour les papyrus médicaux littéraires
Marganne, Marie-Hélène ULg; Mertens, Paul ULg

in Andorlini, Isabella (Ed.) ‘Specimina’ per il Corpus dei Papiri Greci di Medicina. Atti dell'Incontro di studio (Firenze, 28-29 marzo 1996) (1997)

Detailed reference viewed: 15 (0 ULg)
Peer Reviewed
See detailMedici et medica. Extraits du prochain Catalogue des papyrus littéraires grecs et latins (= Mertens-Pack3)
Marganne, Marie-Hélène ULg; Mertens, Paul ULg

in Mandilaras, Basil; Adam, Sophia; Antoniou, Persephone (Eds.) et al Proceedings of the XVIII International Congress of Papyrology. Athens, 25-31 May 1986 (1988)

Detailed reference viewed: 9 (0 ULg)
Full Text
See detailMedicina u papirusima na grckom jeziku nadenim u Egiptu
Marganne, Marie-Hélène ULg

in Lucida Intervalla (2003), 28(2), 74-90

Detailed reference viewed: 35 (9 ULg)
Peer Reviewed
See detailUn médicinaire du XVe siècle (Warfusée)
Boutier, Marie-Guy ULg

in Dialectes de Wallonie (1984), 12

Detailed reference viewed: 24 (4 ULg)
Full Text
Peer Reviewed
See detailMedicine and User Involvement within European Healthcare: a typology for European comparative research
DENT, Mike; Fallon, Catherine ULg; Wendt, Claus et al

in International Journal of Clinical Practice (2011), 65(12), 1218-1220

Detailed reference viewed: 56 (6 ULg)